arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Polaryx Therapeutics, Inc.

PLYX
$1.78 ▼ -0.03 (-1.93%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
17 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Polaryx Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $80.9M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -135.3% ↘
FCF / Share $-0.09 ↘
Trailing P/E —
Price / Book 18.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-8.98M
↑ +70.4% —
FCF / Share Free cash flow per share
$-0.09
↓ -15.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Cash Quality ↑
37

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 3 years · 7 quarters